Plus, news about Beam Therapeutics, Pfizer’s Braftovi regimen, Lonestar Medicines, the NOFLU vaccine consortium and Zura Bio:
🪓 Accent axes DHX9 inhibitor study: The biotech terminated the Phase 1 ...
↧